DSM FIRMENICH AG (DSFIR) fair value: what the stock is really worth
As of Nov 5, 2026: fair value (intrinsic value) of DSM FIRMENICH AG stock CHF 57.82, price CHF 103, that is 44.0% below the price, quality 43 out of 100. Rating: strongly overvalued. Calculated from audited financials with 14 of our 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.
How to read this chart
6‑month range CHF 60.37 – CHF 103.20 · fair‑value band CHF 37.68 – CHF 77.96 · the CHF 103.20 price screens above the CHF 57.82 fair value. As of Nov 3, 2026.
Follow DSM FIRMENICH in your weekly email
Every Wednesday you see whether DSM FIRMENICH is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
DSM-Firmenich AG provides nutrition, health, and beauty solutions in Switzerland, the Netherlands, rest of Europe, the Middle East and Africa, North America, Latin America, China, and rest of Asia.
Show moreShow less
The company operates through four segments: Perfumery & Beauty; Taste, Texture & Health; Health, Nutrition & Care; and Animal Nutrition & Health. The Perfumery & Beauty creates scents using natural, synthetic, and biotech ingredients.
The Taste, Texture & Health segment provides food and beverages solutions, including flavors, natural extracts, and sugar reduction; and food enzymes, hydrocolloids, cultures, natural colorants, nutritional ingredients, and plant-based proteins.
The Health, Nutrition & Care segment provides solutions for the early life nutrition, dietary supplement, pharmaceutical, medical nutrition, biomedical materials, and nutrition improvement markets.
This segment also offers vitamins, nutritional lipids, minerals, carotenoids, botanical nutraceuticals, digestive enzymes, postbiotics, probiotics and prebiotics, and active pharmaceutical ingredients; biomedical solutions; and premix, market-ready, and personalized nutrition solutions, as well as expert services in regulatory affairs and nutrition.
The Animal Nutrition & Health segment offers animal proteins, vitamins, performance solutions, and data-driven precision services. The company was founded in 1902 and is based in Kaiseraugst, Switzerland.
Stock analysis
DSM FIRMENICH AG (DSFIR) currently trades at CHF 103.20, while our model-based Fair Value estimate is CHF 57.82, 44% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of CHF 40.90 per share, and 2 of the 14 models we run sit above the CHF 103.20 price.
Bear case: the Asset-Based group reads lowest at CHF 7.20, and 12 of the 14 models stay below the price. Data coverage for this calculation is medium.
Scenario range: CHF 37.68 (bear) to CHF 77.96 (bull), the price of CHF 103.20 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 43/100 (below-average quality), in the Basic Materials sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
DSM FIRMENICH AG reported revenue of €9.0B in FY2025 versus €8.4B in FY2022, a compound +2.5%/yr. Reported net income was −€1.1B in FY2025.
Key figures
Market cap CHF 25.5B Large · P/S ratio 2.70 · EPS (TTM) CHF −5.06 · Dividend yield 2.7% · Net margin −15.2% · Return on equity 1.9% · Return on assets (EBIT) 1.5% · Operating margin 7.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 29 out of 100 (medium confidence).
What moves the price
For context, the median of 10 Basic Materials peers we cover trades at −41% fair-value upside, at −44%, DSFIR screens richer than that median.
Fair Value models
BearCHF 37.68Fair Value CHF 57.82BullCHF 77.96
Price CHF 103.20 · Downside -44.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCFCHF 26.21CHF 40.90CHF 70.6875
Growth DCFCHF 28.03CHF 42.58CHF 69.9474
Owner EarningsCHF 41.94CHF 63.93CHF 108.5271
All 14 models by family
DCF Models
FCF DCFCHF 26.21CHF 40.90CHF 70.6875
Owner EarningsCHF 41.94CHF 63.93CHF 108.5271
5Y Revenue ExitCHF 18.56CHF 28.70CHF 43.4369
5Y EBITDA ExitCHF 81.69CHF 138.07CHF 212.7771
10Y Revenue ExitCHF 20.43CHF 28.56CHF 37.1865
10Y EBITDA ExitCHF 61.25CHF 99.55CHF 141.5865
Earnings-Based
EPVCHF 14.41CHF 18.16CHF 21.5671
Multiples
EV/EBITCHF 18.89CHF 28.99CHF 39.0865
EV/EBITDACHF 126.17CHF 172.03CHF 217.8867
EV/RevenueCHF 10.22CHF 19.48CHF 28.7552
Asset-Based
NCAV (Graham)CHF 5.37CHF 7.20CHF 10.7554
Growth DCF
Growth DCFCHF 28.03CHF 42.58CHF 69.9474
Rev-Margin DCFCHF 18.56CHF 29.39CHF 42.7869
Economic Profit
ROIC CompounderCHF 14.41CHF 18.16CHF 21.5669
The fair value above starts from this blend and is adjusted for a cyclical trough year.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.29/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−0.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.5%
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
7.8% (2022) → 7.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+20.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+4.2%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in EUR, euro area: IMF forecast 2.2% a year to 2030, 2.6% from 2016 to 2025) that is about +17.6% a year for the price and +1.9% for the forecasts.
AI conclusion: Positive cash flows offer limited support while negative ROE and margins reveal weak pricing power together with scant evidence of a moat in specialty chemicals.
Main risk: Ongoing antitrust investigations and a settlement in the US could lead to further restrictions or costs that squeeze pricing power and margins in the perfumery and beauty ingredients business.
Bull case: The company could strengthen its compliance frameworks and leverage its broader nutrition and health portfolio to offset any pressure on fragrance margins through diversified growth.
Bear case: Further regulatory actions or settlements might constrain pricing flexibility and innovation pace in fragrances, eroding competitiveness against peers in that segment.
dsm-firmenich just completed its share repurchase program and plans to cancel millions of shares by early next year. In its specialty chemicals business serving nutrition and beauty markets, that capital step stands alongside efforts like the new Biond biopharma vitamin range. Our models see the stock as overvalued. Will the reduced share count lift per-share results more than the underlying growth in these segments can sustain?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Chemicals · 726 stocks
Beats the industry median on 3/14 measures
Overall it trails its industry peers.
Valuation
Quality Score43 · Bottom 25%
Fair Value upside−44.0% · Below median
Profitability
Return on equity (12 months)1.9% · Below median
Return on assets−3.7% · Bottom 25%
Net margin (12 months)−15.2% · Bottom 25%
Operating margin (12 months)7.9% · Below median
Growth and dividend
Revenue growth (quarter YoY)0.5% · Below median
Dividend yield (12 months)2.7% · Above median
Balance sheet
Debt / equity0.18× · Above median
Valuation Multiplesvs Specialty Chemicals median · lower = cheaper
P/B1.53× · Cheaper than median
P/S (12 months)3.08× · Priciest 25%
Price / free cash flow42.9× · Priciest 25%
EV/EBITDA22.4× · Priciest 25%
PEG0.72× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)3· sector 67
PAST (return on equity)7· sector 27
HEALTH (low debt)91· sector 95
DIVIDEND (yield)54· sector 30
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "DSM FIRMENICH AG Fair Value". https://www.fairvalue-calculator.com/stock/DSFIR
Frequently asked questions
Is DSM FIRMENICH AG (DSFIR) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of CHF 57.82 versus a price of CHF 103.20, about 44% lower (overvalued).
What is the fair value of DSFIR?
Our model-based fair value for DSM FIRMENICH AG is CHF 57.82 (as of Nov 3, 2026), built from audited fundamentals. The current price: CHF 103.20.
What is the quality score of DSFIR?
DSM FIRMENICH AG has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for DSM FIRMENICH AG (DSFIR)?
Our model-based price target is the fair value of CHF 57.82 (as of Nov 3, 2026) from 14 valuation models. Cautious scenario CHF 37.68, optimistic scenario CHF 77.96. It is a calculation from audited fundamentals, not an analyst target.
What is the DSM FIRMENICH AG stock forecast for 2026?
Our models put fair value at CHF 57.82, about 44% lower versus a price of CHF 103.20 (overvalued). Cautious scenario CHF 37.68, optimistic scenario CHF 77.96. The calculation is refreshed regularly with new filings.
What is the revenue of DSM FIRMENICH AG (DSFIR)?
DSM FIRMENICH AG reported trailing-twelve-month revenue of about €9.1B (latest available figure, as of Nov 3, 2026).
Does DSM FIRMENICH AG pay a dividend?
DSM FIRMENICH AG currently shows a dividend yield of 2.69% relative to its recent price (as of Nov 3, 2026).
What growth is priced into DSM FIRMENICH AG (DSFIR)?
For today's price to be fair in a discounted-cash-flow model, DSM FIRMENICH AG would have to grow free cash flow by +20.2 % per year for five years (discount rate 8.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 3 years revenue grew +2.5 % per year. As of Nov 3, 2026.
What discount rate (WACC) does the fair value of DSFIR use?
Our models discount DSM FIRMENICH AG at 8.0 %: a base by market capitalisation (large), damped by beta 0.53, country premium for Switzerland. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For DSM FIRMENICH AG that is +20.2 % per year a year over ten years, using the same discount rate (8.0 %) and the same formula as our fair value.
How much growth has DSM FIRMENICH AG (DSFIR) delivered so far?
Over the past 3 years revenue at DSM FIRMENICH AG grew +2.5 % a year. The price currently implies +20.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of DSM FIRMENICH AG (DSFIR) growing?
The median revenue growth in the sector is +11.2 % a year. That is the yardstick for the growth priced into DSM FIRMENICH AG (+20.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of DSM FIRMENICH AG (DSFIR)?
The free-cash-flow yield on the price is 2.34 %: that much free cash flow DSM FIRMENICH AG produces per unit of market value. When it exceeds the discount rate of our models (8.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of DSM FIRMENICH AG (DSFIR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For DSM FIRMENICH AG it is CHF 57.82 per share (as of Nov 3, 2026), against a price of CHF 103.20. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).
Is DSM FIRMENICH AG stock overvalued or undervalued in 2026?
As of Nov 3, 2026, DSFIR trades above its calculated fair value: price CHF 103.20, fair value CHF 57.82, a gap of about −44% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of DSFIR?
No. The price is what the market pays today (CHF 103.20); the fair value is what the company's own numbers justify (CHF 57.82). For DSM FIRMENICH AG the two are CHF 45.38 per share apart. That gap is exactly why we show both numbers side by side.
How much is DSM FIRMENICH AG worth?
The market values DSM FIRMENICH AG at about CHF 25.5B (market capitalisation, as of Nov 3, 2026). Per share that is CHF 103.20; our models calculate a fair value of CHF 57.82 per share.
What do the bullish and bearish scenarios say about DSFIR?
Our models span a range for DSM FIRMENICH AG: cautious scenario CHF 37.68, base CHF 57.82, optimistic CHF 77.96 per share (as of Nov 3, 2026, price CHF 103.20). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of DSFIR?
The PEG ratio of DSM FIRMENICH AG is 0.72 (P/E divided by earnings growth, as of Nov 3, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of DSM FIRMENICH AG (DSFIR)?
Balance-sheet figures for DSM FIRMENICH AG (as of Nov 3, 2026): return on equity 1.9%, debt of 0.18 per unit of equity. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
Which stocks are comparable to DSM FIRMENICH AG?
From the same area (Basic Materials) we also value Linde plc, Ecolab Inc, The Sherwin-Williams Company, Nan Ya Plastics Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is DSM FIRMENICH AG stock attractive at the current price?
The data as of Nov 3, 2026: price CHF 103.20, calculated fair value CHF 57.82 (−44%), Quality Score 43/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of DSFIR calculated?
We run DSM FIRMENICH AG through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of CHF 57.82, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.6% above its aggregate fair value. DSM FIRMENICH AG itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of DSM FIRMENICH AG (DSFIR)?
The closing price on Nov 5, 2026 was CHF 103.20. Our model-based fair value is CHF 57.82, about 44% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with DSM FIRMENICH AG right now?
The price sits above even our optimistic bull case (CHF 77.96). The favourable scenario is already priced in. Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range (CHF 37.68 to CHF 77.96) leaves room in how you read the outcome.
Key figures of DSM FIRMENICH AG
How large is the market capitalisation of DSM FIRMENICH AG (DSFIR)?
The market capitalisation of DSM FIRMENICH AG is CHF 25.5B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of DSM FIRMENICH AG (DSFIR)?
The price-to-sales ratio of DSM FIRMENICH AG is 2.70 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of DSM FIRMENICH AG (DSFIR)?
Earnings per share at DSM FIRMENICH AG are CHF −5.06. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of DSM FIRMENICH AG (DSFIR)?
The dividend yield of DSM FIRMENICH AG is 2.7%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of DSM FIRMENICH AG (DSFIR)?
The net margin of DSM FIRMENICH AG is −15.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of DSM FIRMENICH AG (DSFIR)?
The return on equity (ROE) of DSM FIRMENICH AG is 1.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of DSM FIRMENICH AG (DSFIR)?
On an EBIT basis the return on assets of DSM FIRMENICH AG is 1.5% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of DSM FIRMENICH AG (DSFIR)?
The operating margin of DSM FIRMENICH AG is 7.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at DSM FIRMENICH AG (DSFIR)?
Revenue at DSM FIRMENICH AG is growing +0.5% versus a year earlier (3y avg +2.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at DSM FIRMENICH AG (DSFIR)?
Earnings per share at DSM FIRMENICH AG are growing −56.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does DSM FIRMENICH AG (DSFIR) carry?
The net debt of DSM FIRMENICH AG is €3.0B (fiscal year 2025, ≈ 4.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch DSM FIRMENICH AG in the live analysis
One click puts DSM FIRMENICH AG on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 3, 2026